Medical System Network: Confirmation letter
Medical System Network: Half Year Report - Term 27 (2024/04/01 - 2025/03/31)
Medical System Network: Earnings presentation materials for the second quarter (interim period) of the fiscal year ending March 31, 2025
Medical System Network: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (Consolidated)
Medical System Network: Notice regarding revisions to consolidated earnings forecasts for the second quarter (interim period) and full year of the fiscal year ending March 31, 2025
Medical System Network: Explanatory materials for the first quarter of fiscal year ending March 2025.
Medical System Network: Financial report for the first quarter of the fiscal year ending March 2025 [based on Japanese standards] (consolidated).
Medical System Network: Interim report
Medical System Network: Confirmation letter
Medical System Network: Securities report - 26th period (April 1, 2023 - March 31, 2024).
Medical System Network: Full year financial results presentation materials for the fiscal year ending March 31, 2024
Medical System Network: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Medical Systems Network: Quarterly Report - 26th Quarter 3rd Quarter (2023/10/01 to 2023/12/31)
Medical System Network: Confirmation
Medical System Network: Financial results briefing materials for the 3rd quarter of the fiscal year ending March 31, 2024
Medical System Network: Summary of Financial Results for the 3rd Quarter Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Medical System Network: Confirmation letter
Medical System Network: Quarterly Report - 26th Second Quarter (2023/07/01 - 2023/09/30)
Medical System Network: Earnings presentation materials for the 2nd quarter of the fiscal year ending March 31, 2024
Medical System Network: Notice regarding differences between consolidated earnings forecasts and actual values for the second quarter of the fiscal year ending March 31, 2024, revisions to full-year consolidated earnings forecasts, surplus dividends (inter
No Data
No Data